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ABSTRACT
The International Union of Basic and Clinical
Pharmacology/British Pharmacological Society
(IUPHAR/BPS) Guide to PHARMACOLOGY (http://
www.guidetopharmacology.org) is a new open
access resource providing pharmacological,
chemical, genetic, functional and pathophysio-
logical data on the targets of approved and experi-
mental drugs. Created under the auspices of the
IUPHAR and the BPS, the portal provides concise,
peer-reviewed overviews of the key properties of a
wide range of established and potential drug
targets, with in-depth information for a subset of
important targets. The resource is the result of
curation and integration of data from the IUPHAR
Database (IUPHAR-DB) and the published BPS
‘Guide to Receptors and Channels’ (GRAC) compen-
dium. The data are derived from a global network of
expert contributors, and the information is exten-
sively linked to relevant databases, including
ChEMBL, DrugBank, Ensembl, PubChem, UniProt
and PubMed. Each of the 6000 small molecule
and peptide ligands is annotated with manually
curated 2D chemical structures or amino acid
sequences, nomenclature and database links.
Future expansion of the resource will complete the
coverage of all the targets of currently approved
drugs and future candidate targets, alongside edu-
cational resources to guide scientists and students
in pharmacological principles and techniques.
INTRODUCTION
Online resources have become indispensable tools for
pharmacology and drug discovery, in common with
other disciplines in the biomedical sciences. Databases
such as ChEMBL (1) and PubChem (2) provide extensive
information on the bioactivity and chemical structures of
approved and experimental drugs and their interaction
with targets, either manually curated from the medicinal
chemistry literature (ChEMBL) or uploaded by depositors
(PubChem). To complement these large-scale resources,
there is a need for an in-depth, expert-curated overview
of the key targets and ligands, to foster basic and clinical
research and innovative drug discovery, and to educate
the next generation of researchers. The International
Union of Basic and Clinical Pharmacology/British Phar-
macological Society (IUPHAR/BPS) Guide to
PHARMACOLOGY portal (http://www.guidetopharma
cology.org) is being developed to assist research in
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pharmacology, drug discovery and chemical biology in
academia and industry, by providing: (i) an authoritative
synopsis of the complete landscape of current and research
drug targets; (ii) an accurate source of information on the
basic science underlying drug action; (iii) guidance to re-
searchers in selecting appropriate compounds for in vitro
and in vivo experiments, including commercially available
pharmacological tools for each target; and (iv) an
integrated educational resource for researchers, students
and the interested public.
The Guide to PHARMACOLOGY portal has been
online since December 2011. The current release of the
database (October 2013) integrates two well-established
sources. The ﬁrst of these is the IUPHAR Database
[IUPHAR-DB: (3)], which provides in-depth, integrative
views of the pharmacology, genetics, functions and patho-
physiology of important target families, including G
protein-coupled receptors (GPCRs), ion channels and
nuclear hormone receptors (NHRs). The second is the
BPS ‘Guide to Receptors and Channels’ [GRAC: (4)], a
compendium, previously published in print, providing
concise overviews of the key properties of a wider range
of targets than those covered in IUPHAR-DB, together
with their endogenous ligands, experimental drugs,
radiolabelled ligands and probe compounds, with recom-
mended reading lists for newcomers to each ﬁeld.
Management and peer review of the new resource is the
responsibility of the IUPHAR Committee on Receptor
Nomenclature and Drug Classiﬁcation (NC-IUPHAR),
which acts as the scientiﬁc advisory and editorial board.
The organization has an international network of over 700
expert volunteers organized into 60 subcommittees
dealing with individual target families. The subcommittee
members contribute expertize in several ways, including
identifying the key pharmacological properties of each
target, along with quantitative activity data from the
research literature. NC-IUPHAR also directly supports
the Guide to PHARMACOLOGY through its work in
monitoring ‘deorphanization’ of receptors (i.e. identifying
new endogenous ligands), revising receptor nomenclature
in collaboration with HUGO Gene Nomenclature
Committee (HGNC) database (5–7), liaising with
journals, and developing standards and terminology in
quantitative pharmacology (8–10).
The primary sources of data in the Guide to
PHARMACOLOGY are distinct from the medicinal
chemistry and natural product literature extracted by
ChEMBL. Our focus is on data and contextual informa-
tion relevant to the preclinical phases of drug discovery
and includes extensive quantitative and chemical informa-
tion manually curated from the primary research litera-
ture, predominantly from the leading non-specialist
scientiﬁc journals and widely read specialist journals
(Figure 1).
CONTENT AND DATA CURATION
The current version of the database includes pharmaco-
logically relevant data and information on 2485 human
targets including GPCRs, ion channels, NHRs, catalytic
(enzyme linked) receptors, transporters and enzymes
(including all protein kinases) (Table 1). Also included,
is information on the genetics, emerging pharmacology,
functions and pathophysiology of 130 orphan GPCRs (7).
Presently, the resource describes the interactions
between target proteins and 6064 distinct ligand entities
(Table 1). Ligands are listed against targets by their action
(e.g. activator, inhibitor), and also classiﬁed according to
substance types and their status as approved drugs.
Classes include metabolites (a general category for all
biogenic, non-peptide, organic molecules including
lipids, hormones and neurotransmitters), synthetic
organic chemicals (e.g. small molecule drugs), natural
products, mammalian endogenous peptides, synthetic
and other peptides including toxins from non-mammalian
organisms, antibodies, inorganic substances and other,
not readily classiﬁable compounds.
The new database was constructed by integrating data
from IUPHAR-DB (3) and the published GRAC compen-
dium (4). An overview of the curation process is depicted
as an organizational ﬂow chart in Figure 2. New informa-
tion was added to the existing relational database behind
IUPHAR-DB and new webpages were created to display
the integrated information. For each new target, informa-
tion on human, mouse and rat genes and proteins,
including gene symbol, full name, location, gene ID,
UniProt and Ensembl IDs was manually curated from
HGNC (5), the Mouse Genome Database (MGD) at
Mouse Genome Informatics (MGI) (11), the Rat
Genome Database (RGD) (12), UniProt (13) and
Ensembl (14), respectively. In addition, ‘Other names’,
target-speciﬁc ﬁelds such as ‘Principal transduction’, text
from the ‘Overview’ and ‘Comments’ sections and refer-
ence citations (downloaded from PubMed; http://www.
ncbi.nlm.nih.gov/pubmed) were captured from GRAC
and uploaded into the database against a unique Object
ID. For targets present in both IUPHAR-DB and GRAC,
entries were cross-checked and merged. A representative
target family page is shown in Figure 3.
For the integration exercise, all ligands listed in GRAC
were ﬁrst checked against IUPHAR-DB using name-,
synonym- and structure-based comparisons. For over
1000 ligands, there was an existing IUPHAR-DB entry
that matched. The remaining new ligands (1900) were
curated using the workﬂow already established for the
population of IUPHAR-DB with ligand structures (15).
An overview of the process is outlined below.
Interrogation of multiple databases and direct literature
checks captured the correct structural information, nomen-
clature and target mapping for each ligand. All small mol-
ecules were resolved against a PubChem Compound
Identiﬁer (CID) as a primary molecular identiﬁer and rep-
resentative chemical structure (2). Each ligand was then
uploaded into the resource with a unique ID. The quanti-
tative pharmacological activity data of each ligand was
captured from GRAC and uploaded.
Ligands have individual pages (Figure 3) providing 2D
chemical structures or peptide sequences, calculated
physico-chemical properties, classiﬁcation and approval
status for human clinical use, the International Union of
Pure and Applied Chemistry (IUPAC) name and other
2 Nucleic Acids Research, 2013
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names used as synonyms. International Nonproprietary
Names (INNs) are also currently provided for 730 com-
pounds. INNs are the ofﬁcial non-proprietary or generic
names given to pharmaceutical substances, as designated
by the World Health Organization (WHO; http://www.
who.int/medicines/services/inn/en/). For small molecules,
simpliﬁed molecular input line entry speciﬁcation
(SMILES), the IUPAC International Chemical Identiﬁers
(InChI string and InChIKey) and Chemical Abstracts
Service (CAS) registry numbers (http://www.cas.org/
index.html) are provided. Peptides are speciﬁed by one-
and three-letter amino acid sequences, any post-transla-
tional modiﬁcations and details of their protein precursors.
Links are provided to corresponding entries in relevant
bioactivity and chemistry resources including BindingDB
(16), Chemical Entities of Biological Interest (ChEBI) (17),
ChEMBL (1), ChemSpider (18), DrugBank (19), Human
Metabolome Database (HMDB) (20), PharmGKB (21),
RCSB Protein Data Bank (22), UniProt (13) and ZINC
(23). Ligand pages also display a list of structurally
similar ligands and a summary of all biological activity
data for each compound across all the targets.
The ligand page includes an option to display the results
for InChIKey searching in Google, the utility of which has
recently been described (24). While the entire Key is used
for exact-match searches of ChemSpider, the Google
search uses just the inner ‘layer’ of 14 characters
approximating to the basic molecular connectivity. It
will thus retrieve all related entries with isomeric differ-
ences encoded in the outer layer of the Key. The results,
typically returned in <0.5 s with very high speciﬁcity, are
the matches from over 50 million InChIKeys cached by
Google from a wide range of databases and web resources.
IMPLEMENTATION
The data are held in a PostgreSQL relational database
(http://www.postgresql.org), with the exception of ligand
structures and physico-chemical properties, which are
stored in an Oracle database (Oracle Corporation,
Redwood Shores, CA, USA). Curators use custom-built
Java (Oracle Corporation, Redwood Shores, CA, USA)
software to enter and edit data. The public web interface is
implemented using HTML, CSS and JavaScript compo-
nents generated dynamically on the server side by Java
servlets and Java Server Pages. The web application runs
in the Apache Tomcat servlet container (http://tomcat.
apache.org/) on a Linux platform. Ligand structure-
based searching is implemented with the Pinpoint
chemical cartridge (Dotmatics Limited, Bishops
Stortford, UK) and chemical structure editing capability
is provided by the MarvinSketch chemical editor
(ChemAxon Limited, Budapest, Hungary). Ligand
chemical structure formats and identiﬁers were generated
Figure 1. Breakdown of scientiﬁc journals cited in the resource. The chart shows the top 20 most cited journals in the resource, and the contribution
of each journal as a percentage of the total.
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using the Open Babel software (25). IUPAC names were
generated using JChem for Excel (ChemAxon Limited,
Budapest, Hungary) and physico-chemical properties
were generated using the Chemistry Development Kit
(26). Ligand images were created using the NCI/CADD
Chemical Identiﬁer Resolver from the National Cancer
Institute (http://cactus.nci.nih.gov/chemical/structure).
Small molecule ligands with similar structures were clus-
tered using Pipeline Pilot (Accelrys, San Diego, CA, USA)
and peptides with similar sequences were clustered using
h-cd-hit, part of the CD-HIT Suite (27).
WEB INTERFACE
Users can access ‘Target’ and ‘Ligand’ lists and search
tools directly from the portal homepage, as well as from
the navigation bar at the top of every subsequent
webpage. Each class of target (e.g. transporters,
enzymes) is listed according to protein family (e.g. ATP-
binding cassette family, amino acid hydroxylases). The
portal is designed to provide users with access to two
views of pharmacologically relevant data on the targets
in the database. The organization and content of these
two complementary views is described below:
(1) Users are initially presented with concise, searchable
overviews of the properties of each family of targets.
Data on all members of a target family, or subfam-
ily, are presented on a single webpage (Figure 3). The
page for each target family includes a brief overview
of the properties of the target group. Details are
provided on approved nomenclature (where applic-
able, approved by NC-IUPHAR) and synonyms,
human, mouse and rat gene names and links to the
HGNC, MGD, RGD, Ensembl and UniProt data-
bases. Quantitative data are provided on recom-
mended ligands classiﬁed by their mode of action
(e.g. agonists, antagonists, substrates, inhibitors and
radiolabelled ligands) and other information speciﬁc
to the class of target (e.g. the signal transduction
mechanisms used by GPCRs, or the biophysical
properties of ion channels). Overall, the data focus
on human proteins and include only key pharmaco-
logical agents, chosen because they are likely to be
the most useful in the laboratory (i.e. they are select-
ive and available by donation, or from commercial
sources). A list of review articles recommended as
further reading, key references and additional com-
mentary (highlighting, for example, where species dif-
ferences, or ligand metabolism, are potential
confounding factors) are also provided. These pages
are designed to serve as an introduction to a family
of targets and are a useful entry point into the lit-
erature for newcomers to a particular ﬁeld.
(2) From the family overview pages, users can then navi-
gate (via the ‘More detailed page’ links, see Figure 3)
to database pages with more in-depth information
for a subset of important targets, providing
expanded views of the pharmacology, genetics, func-
tions and pathophysiology. These include a longer
introduction to the family and separate pages
providing a comprehensive description of each
target and its function, with information on protein
structure, ligand interactions, signalling mechanisms,
tissue distribution, functional assays and biologically
important variants (e.g. single nucleotide polymorph-
isms and splice variants). Reported ligand inter-
actions may include endogenous ligands, current
and historical licensed and experimental drugs, and
available radiolabelled ligands, along with informa-
tion on their actions (e.g. agonist, allosteric modula-
tor, inhibitor) and quantitative data, where possible
from multiple literature sources. Comparative data
for mouse and rat species are also listed. In
addition, the phenotypes resulting from altered gene
expression (e.g. in genetically altered animals or in
human genetic disorders) are described. An extensive
set of links is provided to other resources including
protein, gene, structure, disease and drug target data-
bases. Family-speciﬁc information and database links
are also provided, such as Enzyme Commission (EC)
numbers and links to the KEGG BRITE hierarchy
describing enzymatic reactions (28). For further
details on the types of information that are
provided in the detailed view see previous publica-
tions (3,15,29).
All literature citations in both views are linked to
PubMed, and all ligand entries are linked to individual
ligand pages providing additional information (as
Table 1. Database statistics
Target class Number of targets
7TM receptors 400
GPCRs including orphans 394
Orphan GPCRs 130
Other 7TM proteins 6
Nuclear hormone receptors 48
Catalytic receptors 223
Ligand-gated ion channels 84
Voltage-gated ion channels 142
Other ion channels 49
Enzymes 1008
Transporters 503
Other protein targets 28
Total number of targets 2485
Chemical class Number of ligands
Synthetic organics 3504
Metabolites 550
Endogenous peptides 687
Other peptides including synthetic peptides 1089
Natural products 161
Antibodies 10
Inorganics 55
Others 8
Approved drugs 559
Withdrawn drugs 11
Drugs with INNs 857
Radioactive ligands 550
Total number of ligands 6064
Number of synonyms 51189
Number of binding constants 41076
Number of references 21774
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described in the section on ‘CONTENT AND DATA
CURATION’ above).
The interface includes a simple search box where users
can enter keywords such as ligand or target names, and
advanced search tools which allow searches by speciﬁc
database ﬁeld, database identiﬁer (e.g. Ensembl ID),
chemical identiﬁer (e.g. standard InChIKey, CAS
registry number) or PubMed identiﬁer. Chemical structure
searches can also be performed by providing a structure in
SMILES format, or drawing a chemical structure using
Figure 2. The Guide to PHARMACOLOGY curation process and organizational chart.
Nucleic Acids Research, 2013 5
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Figure 3. Screenshot of the Cannabinoid receptor family page in the Guide to PHARMACOLOGY, with overlaying screenshots of a typical ligand
page and reference page with link-out to PubMed. Also shown is a link to the ‘More detailed page’ of the CB1 receptor with a screenshot of the top
section of the target page showing the ‘Contents’ table listing the types of information available for this target.
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the structure editor. The search tool can perform exact
match, substructure, similarity and SMARTS-pattern
searches (http://www.daylight.com/dayhtml/doc/theory/
theory.smarts.html). The chemical structure editor is also
accessible from ligand pages; clicking on the ligand image
loads the structure into the editor where it can be modiﬁed
and used to search the database. Search results indicate
which database ﬁelds matched the query term, and links
are provided to the relevant database entries.
Extensive help pages and a tutorial on how to use the
resource are also provided. The help page can be accessed
via linked icons within database ﬁelds as well as from the
navigation menu and home page. The help page includes
deﬁnitions of terms used to describe the data displayed on
the site, in addition to providing a detailed guide to using
the various search functions.
COMPARISON WITH OTHER RESOURCES
There are other databases that have a degree of conceptual
and content overlap with the Guide to PHA-
RMACOLOGY, some of which are included in this
issue. Of these, ChEMBL, DrugBank and Therapeutic
Target Database (TTD) (30) are the closest. However,
the Guide to PHARMACOLOGY differs from these re-
sources in a number of important ways. Firstly, we restrict
the range of protein targets and ligands to those most
relevant to therapeutics and drug discovery, chosen with
the exercise of curatorial judgement and backed by our
network of experts, with a focus on the quality and
depth of annotation. Secondly, this is subject to review
and quality control, not only by our international expert
committee members operating as a de facto network of
‘super-curators’, but also via user feedback. Thirdly, we
curate activity data for research compounds from primary
literature sources, including posters and patents, rather
than from review articles, with a focus on the interactions
of each compound with its data-supported primary target
(e.g. Angiotensin-converting enzyme (ACE) for captopril).
Fourthly, the data can be annotated with free-text
comments that would otherwise not easily ﬁt into
database schema. These include information on alterna-
tive isomers and salt forms. An example here are the eight
approved drug–prodrug pairs for ACE inhibitors that
present a particular curatorial challenge (e.g. see
http://www.guidetopharmacology.org/GRAC/LigandDis-
playForward?ligandId=6352). These 16 structures are not
both explicitly linked and activity-mapped in other
databases.
Another example that illustrates the differences between
the three databases is atorvastatin. In the Guide to
PHARMACOLOGY (http://www.guidetopharmacology.
org/GRAC/LigandDisplayForward?tab=biology&ligan-
dId=2949), there are three activity mappings between this
ligand and the primary drug target hydrox-
ymethylglutaryl-CoA reductase (HMGCR) with both a
Ki (14 nM) and an IC50 for human (8 nM), together with
an IC50 for rat (1.16 nM). The equivalent DrugBank entry
(DB01076) is mapped to 3 targets, 11 enzymes and 9 trans-
porters, but these include associations from the literature
that are not all supported by directly measured molecular
interactions. The ChEMBL entry (CHEMBL1487) is
assay-mapped to 117 proteins and lists 217 IC50 values,
including proteins in the DRUGMATRIX screen and
some antimalarial parasite results. There are four IC50
values for the rat and three for the human enzyme. In com-
parison, the two literature references for atorvastatin in
TTD are not the same as from the other three sources.
Mapping differences between ChEMBL, DrugBank and
TTD have previously been explored in detail (24,31), but
the overall picture between these and the Guide to
PHARMACOLOGY is one of complementarity. We thus
suggest that pharmacologically oriented users might ﬁnd
the curatorially selected set of stringent activity mappings
in the Guide to PHARMACOLOGY a simpler entry point
(indeed we designed it with this in mind) but we provide
extensive linking to the other high-value resources.
SUMMARY AND FUTURE DIRECTIONS
Our goal is to complete a stringently curated direct
mapping (where the primary literature data permits)
between chemical structures and their primary molecular
targets, initially for targets of approved drugs, but extend-
ing this to clinical and research targets. Published listings
and the exact deﬁnitions for these categories vary widely,
but indicate a range of 200–300 for the former and
500–1000 for the latter (32–36). Possible reasons for
disparities in these numbers are indicated in database
comparison reports (24,31). We are also in the process
of updating our ligand structure submissions to
PubChem, facilitating UniProt cross references for their
targets and reviewing new information sources for
possible inclusion.
The creation of the new portal reﬂects our intention to
develop the resource into a comprehensive online guide,
which will include educational resources, and to produce a
‘Concise Guide to PHARMACOLOGY’, to be published
in PDF format at two yearly intervals, as a supplement to
the British Journal of Pharmacology. The ‘Concise Guide
to PHARMACOLOGY’, which replaces GRAC, will be a
biennial snapshot of succinct overviews of the properties
of each target family, intended to be a quick desktop ref-
erence guide. Additionally, this will provide a permanent
record (DOI: digital object identiﬁer) that will survive
database updates and therefore allow the precise context
of the database to be understood at any time in the future
(37).
Since the Guide to PHARMACOLOGY portal now in-
tegrates data from the printed GRAC compendium and
IUPHAR-DB, we are planning a phased retirement of
IUPHAR-DB. The current URL (http://www.iuphar-db.
org) will remain active, with appropriate notices directing
users to the Guide to PHARMACOLOGY portal.
DATA ACCESS
The Guide to PHARMACOLOGY is available online at
http://www.guidetopharmacology.org. The website
includes downloadable ﬁles containing current receptor
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and channel lists, NC-IUPHAR nomenclature, synonyms,
genetic information, HGNC gene nomenclature and iden-
tiﬁers, and other database accessions. Other ﬁle formats
are available by emailing enquiries@guidetopharma-
cology.org. Information on linking to Guide to
PHARMACOLOGY pages is provided at http://www.
guidetopharmacology.org/linking.jsp. To further facilitate
external programmatic and user access to the database, we
are developing an application programming interface
(API) and Web services. This will allow our content to
be exploited in new integration initiatives such as Open
PHACTS (38), of which we are already an associate
member. The database is licensed under the Open Data
Commons Open Database License (ODbL) (http://
opendatacommons.org/licenses/odbl/), and its contents
are licensed under the Creative Commons Attribution-
ShareAlike 3.0 Unported license (http://creativecommons
.org/licenses/by-sa/3.0/).
CITING THE RESOURCE
For a general citation of the resource we recommend
citing this article. Citation formats for speciﬁc target
pages are provided on the website.
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